Efficacy and Safety of Herbal Medicine Bojungikki-Tang in Combination with Pembrolizumab versus Pembrolizumab Monotherapy for Stage IV Non-Small Cell Lung Cancer: Study Protocol for a Randomized, Open-Label, Double-Arm, Multicenter Trial
This study will provide novel evidence regarding survival outcomes, quality of life, and safety profiles of combined ICI and BJIKT therapy for advanced NSCLC. The exploratory data will contribute to tailoring treatments to immune-based SD types in NSCLC patients.
Authors
- Eunbyul Cho (ORCID: https://orcid.org/0000-0003-3431-1109)
- Jin-Mu Yi (ORCID: https://orcid.org/0000-0002-8717-3953)
- Mi-Kyung Jeong (ORCID: https://orcid.org/0000-0002-0239-0159)
- Seung Hun Jang (ORCID: https://orcid.org/0000-0001-5457-5780)
- Dong Won Park (ORCID: https://orcid.org/0000-0002-4538-6045)
- Seung Hyeun Lee (ORCID: https://orcid.org/0000-0002-7666-313X)
- Sung Yong Lee (ORCID: https://orcid.org/0000-0002-8693-5792)
- Sang‐Won Um (ORCID: https://orcid.org/0000-0002-9765-9068)
- Seung Joon Kim (ORCID: https://orcid.org/0000-0003-4836-8958)
- Jaemoo Chun (ORCID: https://orcid.org/0000-0003-4191-4063)
- Seong Hoon Yoon (ORCID: https://orcid.org/0000-0002-2075-4702)
- Ho G. Jang (ORCID: https://orcid.org/0000-0001-9869-4562)
Institutions
- Korea University Medical Center (KR)
- Kyung Hee University (KR)
- Korea Institute of Oriental Medicine (KR)
- Pusan National University Yangsan Hospital (KR)
- Hallym University Sacred Heart Hospital (KR)
- Hanyang University (KR)
- Sungkyunkwan University (KR)
- Catholic University of Korea (KR)
Publication Details
- Journal
- Integrative Cancer Therapies
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1177/15347354251319339
- Citations
- 5
- Primary Topic
- Pharmacological Effects of Natural Compounds
- Type
- article
- Field-Weighted Citation Impact
- 7.79
Funders
- Korea Institute of Oriental Medicine